Joerg Matthiessen

Economist & Strategy Consultant

Joerg Matthiessen

Economist & Strategy Consultant

“When I first was diagnosed with two types of cancer, the doctors in my local community hospital wanted to operate immediately without any kind of molecular profiling. I am convinced that I would not be alive now if I hadn’t searched for alternatives.”

In 2016, Joerg was diagnosed with two types of cancer, one in stage 4 and one in stage 3. The stage 3 cancer was a so-called “age cancer” that was slow growing and able to be removed surgically. The stage 4 cancer (Cholangiocarcinoma) was highly aggressive and needed an urgent systemic treatment. After several rounds of mostly ineffective chemotherapy, Joerg was put on a new immunotherapy drug, Opdivo, which had just been approved by the FDA for tumors such as Joerg’s.

The Opdivo was highly effective and resulted in the remission of the stage 4 cancer. Joerg reached the 2-year milestone of taking Opdivo and his oncologists decided to stop the treatment, at least temporarily, as there is simply not enough experience with the long-term use of the drug. Plus, Joerg was beginning to experience some side effects. Earlier in 2019, Joerg had heard of MyCancerDB and decided to join as a Founding Member. It is his hope that MyCancerDB will provide access to an effective, highly personalized treatment option, with potentially fewer side effects, for him and for others in the near future.

The Next Step is Here

Get in Touch